Anita Anne Hamilton

USPTO Granted Patents = 19 (Patent Applications = 2)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 1)

Average Co-Inventor Count = 3.3

ph-index = 9

Forward Citations = 373(Granted Patents)

Company Filing History:

Emd Lexigen Research Center Corp.

Amgen Research (munich) Gmbh

patents

Years Active: 2005-2015

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9102736 - Multispecific deimmunized CD3-binders (2015-08-11),

2. 8926973 - Reducing the immunogenicity of fusion proteins (2015-01-06),

3. 8076459 - Multispecfic deimmunized CD3-binders (2011-12-13),

4. 7973150 - Reducing the immunogenicity of fusion proteins (2011-07-05),

5. 7910104 - Modified anti-CD52 antibody (2011-03-22),

6. 7615217 - Artificial proteins with reduced immunogenicity (2009-11-10),

7. 7601814 - Reducing the immunogenicity of fusion proteins (2009-10-13),

8. 7514078 - Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies (2009-04-07),

9. 7465572 - De-immunized streptokinase (2008-12-16),

10. 7459143 - Carrier molecules (2008-12-02),

11. 7430476 - Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity (2008-09-30),

12. 7264806 - Modified anti-CD52 antibody (2007-09-04),

13. 7189830 - Anti-KSA/IL-2 fusion proteins with reduced immunogenicity (2007-03-13),

14. 7132511 - Modified anti-EGFR antibodies with reduced immunogenicity (2006-11-07),

15. 7125689 - Method for rendering streptokinase less immunogenic to a human (2006-10-24),

Title: Innovator Spotlight: Anita Anne Hamilton, Pioneering Biopharmaceuticals

Introduction: Anita Anne Hamilton, based in Aberdeen, GB, is a distinguished inventor known for her significant contributions to the field of biopharmaceuticals. With a remarkable portfolio of 19 patents, Hamilton's work focuses on innovative therapeutic solutions aimed at improving patient outcomes.

Latest Patents: Among her latest inventions are groundbreaking patents on multispecific deimmunized CD3-binders. This innovative construct presents a cytotoxically active binding mechanism that targets human CD3, accompanied by a nucleic acid sequence essential for its production. Additionally, Hamilton has developed methods to reduce the immunogenicity of fusion proteins. This invention detailed compositions that modify the junction region of fusion proteins, thereby diminishing their interaction with T-cell receptors, which could enhance therapeutic efficacy.

Career Highlights: Throughout her career, Anita has been associated with prestigious organizations like Merck Patent GmbH and Biovation Limited. Her experience in these companies has allowed her to refine her skills in patent research and development, paving the way for her notable inventions in the biopharmaceutical sector.

Collaborations: Hamilton has collaborated with esteemed professionals such as Stephen Williams and Francis J. Carr. These partnerships have facilitated significant advancements in her research, enabling her to tackle complex challenges in the field of immunotherapy and beyond.

Conclusion: Anita Anne Hamilton stands out as a prominent figure in biopharmaceutical innovations. Her inventive spirit and dedication to developing effective treatments have led to significant advancements that have the potential to transform current therapeutic practices. As her portfolio continues to grow, the impact of her inventions on healthcare remains poised for a profound influence.

This text is generated by artificial intelligence and may not be accurate.